Editorial Guidelines for Peer-Review Papers

This guide includes information about submitting papers for peer review to BioPharm International.

BioPharm International welcomes original manuscripts for peer review and possible publication on topics related to drug development and manufacturing.

Readers are doctorate-level scientists, senior-level scientists, or senior production professionals interested in objective, well researched, and scientifically/technically relevant content on the following:

- Drug substance manufacturing
- Formulation development
- Drug-delivery technologies
- Scale-up and process development
- Finished drug product manufacturing
- Analytical methods development
- Regulatory and pharmacopeial requirements and compliance, quality assurance, quality control, and validation
- Bio/pharmaceutical facility design, plant operation, engineering, process control, and automation
- Quality by design, continuous processing, and emerging manufacturing approaches.

Accepted manuscripts are scheduled for publication in BioPharm International. Articles are also posted on www.BioPharmInternational.com.
Review Process

*BioPharm International* follows peer-review procedures standard for scholarly and technical journals. Submitted papers are initially screened by the editors, then submitted for formal review by a member(s) of the editorial advisory board, who will review the article for technical interest and content in a double-blind review process. An editor communicates questions, queries, or requests for additional information/data between the reviewer and author.

The review, revision, and acceptance process typically takes 6 to 8 weeks.

Article acceptance is conditioned on the reviewer’s approval. Once accepted for publication, an article is published within 3 to 5 months. A galley proof is provided to the corresponding author for review prior to publication.

Manuscripts for peer review are reviewed upon submission; accepted publication are scheduled for publication in the order of acceptance.
Peer-Review Categories
Papers submitted for peer review may fall into one of four main categories:

**Standard data-driven, novel research paper**
Peer-review articles that present novel scientific findings and original data that advance a technology, a process, a synthesis, a formulation/drug delivery method, or manufacturing scalability or operability. [2000–3600 words, up to 5 figures/tables]

Peer-review papers offering original research follow a general format as follows:
1. **Abstract**: 200 words briefly describes the hypothesis and conclusion
2. **Introduction**: Sets the hypothesis within a context of the state of the art and explaining how the presented data change or advance the current theory or practice
3. **Materials and Methods**: Sets out the experimental procedure, including all equipment used, settings, buffer compositions and concentrations, ingredients, and other materials and procedures. The information should be detailed enough to allow any other researcher to duplicate the experiments described. Experimental and control experiments must be described.
4. **Results**: Presents data in tabular format, spectra, and other graphics summarizing data values and showing standard deviations. Results must include those for the experimental and control conditions.
5. **Discussion**: The author reviews the data and supports the conclusions. The author may raise alternate hypotheses and demonstrate how the data fit one of these in particular. They may also suggest future experiments that will eliminate other hypotheses or advance the current one.
6. **Conclusion**: A short section restates the hypothesis that has been proved in the article. Authors may also choose to comment on current and potential future applications of the work.
7. **References**: Throughout the paper, the author should cite sources in which data were presented about methods used, supporting or competing hypotheses, or conclusions related to the work being presented.

**Technical case studies/technical application notes**
Peer-review articles in a technical case study format provide the reader with practical guidance and understanding to resolve a problem or challenge. The article is evaluated based on whether it provides sound scientific/technical understanding of a problem/issue and related guidance for scientific/technical personnel specifically involved in this field. The submission should include an introduction; explanation of materials and methods used a presentation of results; a review and explanation of data; and a conclusion of the findings. [1800-2000 words, up to 3 figures/tables]
**Topical literature or patent review**
A peer-review paper offering a topical literature or patents review informs the reader of the latest scientific/technical advances in a given area with proper citations to literature and/or patents. The paper summarizes and objectively explains the importance of the work in this field and/or comparison of this work to other approaches in the field. [2000–3000 words, up to 3 figures/tables]

**Science-based opinion papers**
Peer-review articles that offer an opinion on current industry thinking and practices or other developments must be supported by scientific/technical information. The reviewer does not evaluate the opinion per se, but evaluates whether sufficient and accurate science/technical support is offered in any such opinion. [1000–1500 words]

For all papers, performance-related claims must be supported by references to published literature such as journal articles, conference proceedings/posters, or experimental data. See the *BioPharm International* Submission Guidelines for reference styles and formatting.
Originality and Licensing

**Originality and rights**
Manuscripts are reviewed with the understanding that they have not been published previously in any format—print or electronic—are not ghostwritten, and are not under consideration for publication elsewhere, including on the Internet.

All articles undergo a thorough check for plagiarism; if plagiarism is found, the article will automatically be rejected, and the author(s) will be banned from publishing in *BioPharm International* and its sister publications.

**Image, figure, and table rights**
The author must own the rights to all submitted images, tables, and figures. Graphics from other sources or third-party sources will not be accepted for publication.

**License agreement**
The author and any coauthors are required to sign a license agreement before a manuscript is accepted for publication to provide UBM (a part of Informa plc) permission to publish the original article and its associated figures/tables in print and online.

Consult the *BioPharm International* Submission Guidelines for complete instructions on article formatting, specifications for images and figures, style guides for references, figures, and more details.

**Article inquiries**
Article inquiries can be sent to:
Rita Peters, editorial director, rita.peters@ubm.com
Susan Haigney, managing editor, susan.haigney@ubm.com
Feliza Mirasol, science editor, feliza.mirasol@ubm.com